Compare BHM & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | LITS |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 44.4M |
| IPO Year | 2022 | N/A |
| Metric | BHM | LITS |
|---|---|---|
| Price | $10.51 | $1.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 11.2K | ★ 309.2K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.05 | $0.95 |
| 52 Week High | $14.81 | $3.03 |
| Indicator | BHM | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 47.57 |
| Support Level | $9.90 | $1.13 |
| Resistance Level | $11.89 | $1.16 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.00 | 29.61 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.